脑部放疗，上午比下午敏感许多！
, Q" p- u# g1 {, f
' {: g# R9 |2 z4 g& y: c! I) c/ n( m
Cancer 2011 Jan 15;117(2):414-20. doi: 10.1002/cncr.25423. Epub 2010 Sep 9.
$ C) a( B& n; e* yGamma knife radiosurgery for brain metastasis of nonsmall cell lung cancer: is there a difference in outcome between morning and afternoon treatment?. V% H2 ^3 _* v1 l7 ?: y
Rahn DA 3rd, Ray DK, Schlesinger DJ, Steiner L, Sheehan JP, O'Quigley JM, Rich T.
0 d6 R9 G, {& `# V% u$ pSourceDepartment of Radiation Oncology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA., ~: b% U: g% g9 d1 R7 r
' ~$ w6 w. Z) F4 t' h, o
Abstract/ J( p6 ?4 B0 N3 H
BACKGROUND: Circadian cell-cycle progression causes fluctuating radiosensitivity in many tissues, which could affect clinical outcomes. The purpose of this study was to determine whether outcomes of single-session gamma knife radiosurgery (GKRS) for metastatic nonsmall cell lung cancer (NSCLC) differ based on treatment time.
, p5 M1 o6 I9 U o6 h2 F7 ?1 E* h5 `
METHODS: Fifty-eight patients received GKRS between 10:00 am and 12:30 pm and 39 patients received GKRS between 12:30 pm and 3:00 pm. The mean peripheral dose was 18.6 Gy. The mean tumor size was 7.3 cm³. Magnetic resonance imaging was used to score local control at 3 months. Cause of death (COD) was categorized as central nervous system (CNS)-related or systemic.
0 a& B/ r5 L" E5 w# T `5 m8 C" y/ M" ]8 [- y' {2 B8 U
RESULTS: Demographic and disease characteristics of the 2 groups were similar. Local control at 3 months was achieved in 97% (35/36) of patients who underwent GKRS early in the day versus 67% (8/12) of patients who underwent GKRS later in the day (chi-square, P = .014). Early GKRS was associated with better survival (median 9.5 months) than late GKRS (median 5 months) (Kaplan-Meier log-rank test, P = .025). Factors contributing to better survival in a Cox regression model included early treatment time (P = .004) and recursive partition analysis class (P < .001). Cause of death in the early treatment group was CNS-related in 6% (3/47) of patients versus 24% (8/34) of patients in the late treatment group (chi-square test, P = .026).* h+ f9 v, x5 c7 \4 W% D5 t
$ ?- [. r b# G8 }
CONCLUSIONS: GKRS for metastatic NSCLC had better local control, better survival, and a lower rate of CNS-related cause of death when given earlier in the day versus later in the day. These retrospective data should encourage future study in brain radiosurgery and non-CNS stereotactic body radiotherapy series.3 j+ V7 |% N; l" o" s( Y0 M
q$ p8 N; M1 p$ i/ y8 @& _* d
|
SMARCA4-NSCLC 盲试靶向药有效！！
首先感慨一下今天真的是个好日子。努力了进三个月的治疗终于有了重大进展。
复查结果
肺腺癌术后一年复查，这是复发转移了
【基本病情：2024年4月底确诊肺癌，五月初手术，术后分期3A期，肺腺癌，淋巴结转移，
无靶点 her2扩增 二线白紫耐药后怎么
家父今年62岁，22年11月份颈部淋巴结穿刺，确诊肺低分化腺癌，分期是TxN3M1，基因检测
肺癌基因检测突变频率最高的TP53，有
作者：Tony
说起肿瘤界最著名的基因，TP53是个绕不开的话题。
在基因检测报告中，病友
肿瘤患者放化疗后如何补充营养，专家
整理者：pear审核人：王闫飞教授放化疗在对抗肿瘤的过程中起着至关重要的作用，但同时
' o: j, |! C- n; G
显身卡
